<SEC-DOCUMENT>0001193125-16-492318.txt : 20160304
<SEC-HEADER>0001193125-16-492318.hdr.sgml : 20160304
<ACCEPTANCE-DATETIME>20160304072735
ACCESSION NUMBER:		0001193125-16-492318
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160304
FILED AS OF DATE:		20160304
DATE AS OF CHANGE:		20160304

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prima BioMed Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		161483581

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d155900d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13A-16</FONT> OR
<FONT STYLE="white-space:nowrap">15D-16</FONT> UNDER THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated March 4, 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35428</FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>RIMA</SMALL> B<SMALL>IO</SMALL>M<SMALL>ED</SMALL> L<SMALL>TD</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s Name) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by
check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;</FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;</FONT><FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (1):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;
&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): Not applicable. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: March 4, 2016 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>Prima BioMed Ltd</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">PRIMA BIOMED RECEIVES NASDAQ NOTICE OF BID PRICE DEFICIENCY</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d155900dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g155900g78k79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX</B>/<B>Med</B>ia Relea<B>s</B>e<B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Code: NASDAQ: PBMD; ASX: PRR) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4&nbsp;March 2016 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRIMA BIOMED RECEIVES NASDAQ NOTICE OF BID PRICE DEFICIENCY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA - Prima BioMed Ltd (NASDAQ: PBMD; ASX: PRR) (&#147;Prima&#148;, the &#147;Company&#148;), has received notification from the Listing
Qualifications Department of The NASDAQ Stock Market (the &#147;Staff&#148;) indicating that, for the period from January&nbsp;13, 2016 through February&nbsp;26, 2016, the closing bid price of the Company&#146;s American Depositary Shares, or ADS,
had not been maintained at the minimum required closing bid price of at least US$1.00 per share as required for continued listing on The NASDAQ Global Market pursuant to NASDAQ Listing Rule 5450(a)(1) (the &#147;Minimum Bid Price Rule&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima has a period of 180-calendar days, or until August&nbsp;29, 2016, to regain compliance with the Minimum Bid Price Rule. If within any time during the
180-day period the minimum closing bid price per share of the ADSs closes at or above US$1.00 for a minimum of ten consecutive business days, the Staff will provide written notification to the Company that it complies with the Minimum Bid Price Rule
and the matter will be closed. Prima&#146;s management is looking into various options available to the Company in order to regain compliance and maintain its continued listing on The NASDAQ Global Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima&#146;s ADSs will continue to trade uninterrupted on The NASDAQ Global Market under the symbol &#147;PBMD&#148;. The Company&#146;s ordinary shares which
are traded on the Australian Stock Exchange (&#147;ASX&#148;) under the symbol &#147;PRR&#148; are in full compliance with ASX listing requirements and are completely independent of the NASDAQ listing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that Prima does not regain compliance within the above mentioned period, the Company may be eligible to receive an additional 180-day compliance
period; such additional compliance period would be available provided that the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The NASDAQ Capital Market, with the
exception of the minimum bid price requirement, based on the Company&#146;s most recent public filings and provides written notice of its intention to cure the minimum bid price deficiency. If it appears to the Staff that the Company will not be
able to cure the deficiency, or if the Company is not otherwise eligible for the additional compliance period, the Staff would provide written notification to the Company that its ADSs are subject to delisting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow" ALIGN="center"><B>Prima BioMed Ltd</B>,
Level 12, 95 Pitt Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow" ALIGN="center">Phone: +61 2 8315 7003 Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow" ALIGN="center">www.primabiomed.com.au ABN: 90 009 237 889 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Prima BioMed </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment
of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima&#146;s current lead product is IMP321, based on the LAG-3 immune control mechanism, which plays a vital role in the regulation of the T cell immune
response. IMP321, which is a soluble LAG-3 Ig fusion protein, is an APC activator boosting T cell responses for cancer chemo-immunotherapy and in other combinations and has completed early Phase II trials. A number of additional LAG-3 products,
including antibodies for immune response modulation in autoimmunity and cancer, are being developed by large pharmaceutical partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is
listed on the Australian Stock Exchange and on the NASDAQ in the US. Please visit <U>http://www.primabiomed.com.au</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information please
contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew Beck, The Trout
Group LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (646)&nbsp;378-2933; mbeck@troutgroup.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr Matthew Gregorowski,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)&nbsp;422 534 755; mgregorowski@citadelmagnus.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow" ALIGN="center"><B>Prima BioMed Ltd</B>,
Level 12, 95 Pitt Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow" ALIGN="center">Phone: +61 2 8315 7003 Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow" ALIGN="center">www.primabiomed.com.au ABN: 90 009 237 889 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g155900g78k79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g155900g78k79.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % &!K7BBUTR_M=)MT-WK%WDP6B'G ZNY_A4>I_"F!K^;Y4
M >=E7 ^9LX4&D[+<$FW9(I#Q#H[R^4NJ6I?IM\T5*G W>&K)7Y&0:YK,FB6?
M]HFV,]A$"UR8N9(U_O*O\0'<=<52L]C#K9HT;#4+34;**\LITN+:9=T<D9R&
M% :]2W0 4P"D 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %,
MI % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0!C>*-=A\->&K_5Y^4M8RP7^\W11^)(H \]^"<%QJMIK'BO5'
M$^I7]R8A,W+*B@94>@R>GL*;T ?\4KVZ&IVMEO=+7RM^ <!VSW]<8KAQ,I)V
M1]/DM&E*+G+>YY]@=A7!S6/J7JK(]4^&-[=7FEWMG<L9;:!@L>_G@CE?<5Z6
M&DVM3XO.J,*55.&YQ_A#5&\#_%_4O!J.[:1>3?Z/&S9$+L-RX^N<?E76>&>Y
M.VR%F')"DT >(:5\7?'.NB]?2/"MI>QV;8E\MVR.N.,\]#TH Z?PI\6(?$VC
M:L6L?L>L:=;23M;.25<*#R#UZ\$'D4 <SH_Q:\>Z_I\]]I7A*TO+>W.)#$[9
M!QG&,Y/X4 =A\.?B4GCB.\MKBQ^PZE:#<\08E67ID9Y'/!!H B^&?Q#U#QOJ
M&L6][96]NMB5"&(MELLPYS_NT -UKXG'2?BE8>%1!"UI-L2:=B=Z2/G:!VQ]
MW\Z +'B[XC'POXXT+0C!"]O?$?:)6)W1AFVKC\?6@#OP30!X]X^^,MYX8\4S
M:1I6G6]VMJ@\]Y=V0YYP,=@"/Q- 'J>BZI#K6C6>IVS!H;J%95(]QTH OT@/
M(?$/Q1\36?Q!N?"NBZ)9WTJ$"(.[!G^3<>^/6@!_A_XM:J?&$/AOQ7X?&F7,
M[!(VC8G#'ID'J#ZBF!KZA\0-0L_BU:>#TL[=K2=59IR3O&5)^G:@"7QY\3(O
M"=U!I.GV+:EKEP 8[9<X )X)QSDXZ"@#GH_B[K^A:E;1>-?"K:997'"W$6X[
M?J#U]QG- 'INIZS;Z;X?NM8+![>"W:X!7^( 9&/K0!R?PU^($WC30]0OM1@@
MM)+.7#K&QVA-N<G/X_E0 _X<^/V\=+J[-!% +.XVQ!"<M$<[6.>_% ',WGQ1
M\7S>-M6\.Z#X>L[Z2QD8#+LK%01R>0.] '5^#]<\;:IJDT/B7PY#IEHL6Z.6
M.3<6?(XZGMF@#B[;XK^--6\0:GI>A^&K.]:QD<-B1@=H8J#R1Z4 7M$^-3)K
M*Z1XOT631KEG""09**2<#<#R![C(H ];4YZ'-(!U !0 4 % !0 4 % !0 4
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M=N",C>"S%L=.@ % ''?#_P 1^+_#?A#5;KP_I4%U8HX:XGD!8Q-M_NYY&.:
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M-*UE$6+=2=@ZT ;=( H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MJO('_P!V0&FIQ?4R=.<=TRR'!&1S]#3NNY#5@#>QI_,5Q<^_-,!/FH 4$]Z
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MA18 ##UH 7(I &:  &@!:8!2 * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@!&Z4 ?/_Q*T34/%?QIT_0FD,-M) GE/V5.2Y'OP1^5
M,#?^*7PVTF/P1]NTBU2UN-)BS^[4#SX^ =YQR<<Y^M '5?"*6>7X8Z*TY8MY
M;*I8\E0YV_IB@#N*0!0 4P"@ H * "@ H * "@ H * "@ H * "@ H * "@
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M?\+%U0?\NEK_ ./?XT?6GV#^QZ?<3_A8VJ#_ )=+7_Q[_&CZV^P?V/3[B?\
M"Q]5_P"?2U_\>_QH^M2[#_L>GW$/Q(U4?\NEK^3?XT?6I!_8]/N)_P +'U;_
M )];7\F_QH^M/L/^QZ?<8?B1K Z6]J/P/^-'UI]BEE%+N-/Q(UGM#:C_ ( ?
M\:/K4NQ7]D4>[&'XCZY_<M1_VS/^-3]:F/\ LBAW8P_$;7NWV4?]LO\ Z]'U
MJ8_[(H=V1-\0O$!_Y;6X^D7_ ->E]9FRUE.'\R%O'GB)NEZJ_2):7UB92RG#
MKH5W\9>(7/.J2C_= ']*EUY]S19;AU]D@?Q1KS]=6NA]'Q2]M/N:K X9?81
M^OZPPYU6[/\ VV-+VL^Y?U2A_(B!M4U!SEK^Y)]Y6H]I/N-86BMHHA>[N7'S
M7$Q^LA/]:/:2?4T5"DMHHA;YCELGZ\TN:7<M4X+H)M'88J;LI)+8,#TI:C#-
M ]4-HL@N@I6["O8*I:"=GN%*XQ#3N/02EJ'H?2]>X?G 4 % !0 4 % !0 4
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M4(: 0TT#&T @H*$H 2@!&Z4 )0 'I0BA*8@H *0T-H&)0(*8@H .U(8V@84
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M2]>X?G 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MZ+,?,NXT$>M(>^PM*XTF(>*:8[604Q!0/40TKH>HE*X"4QA0(*8K!VI#&T;
M%*X'TO7NGYP% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % "8H ,4 &* #%, QQP: $Q2L+43&
M#UHT ,>]%D,0Q(>JJ?J*5HOH/F:ZD365L_W[>)OJ@I<D>P_:3[D3Z5ISC#V-
MN1[Q"CDCV*5:HMI,KR>'=$E&'TNU/_;(4O9P[%K%5E]IE63P7X=D'.E0C_=R
M/Y4O8P?0T6.Q"VDRL_P_\./TL&3W65O\:3H0-(YCB(Z\Q"?ASX>/_+O,/I,:
M7U>)HLUQ*ZD3?#306Z&Z7Z2__6J7AHLI9MB5U*\GPMTHC]W>72?4@_TJ?JL3
M19SB%N59/A3;G_5ZM*/]Z,&E]51K'.ZO6)6;X3R?P:PO_ H?_KU/U0T6=OK
MA;X4WJ_=U6 _6,C^M2\(5_;<>L"%OA9JH^[?6I^NX4OJK*6=4^L2!_ACKBY
MFM&_X&1_2AX6?0TCG-'JF5W^&_B-/NPV[_285#PU5&ZSC#>:^15?P%XEC_YA
MN[_=D4_UI?5ZI?\ :^&_F?W'NE>H?%A0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4P ]* &TA(4=*$,0TQ"B@8AZTQA0)ABDR0%(I"T"$IB%I,H;2$MPH&Q1TJA!
2TI A!T-!0=ZD052)%[512/_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
